At BRL Medicine Inc., we aim to become the world's leading Cellular & Gene pharmaceutical company in the era of new commercial civilization, with the mission of "Through innovation led by gene editing, develop breakthrough human therapeutics and benefit the whole world". With its independent R&D center and the "Shanghai Research Center for Gene Editing and Cell Therapy", jointly established by BRL Medicine and university, BRL Medicine has obtained more than 100 patent achievements, and initiated 19 Investigator-Initiated clinical Trials (IIT) in 20 leading hospitals in China, with many pipeline projects have entered into IND application stage. Among them, gene editing projects for β-thalassemia, PD1 knockout non-viral targeted integration CAR-T and UCART have achieved excellent clinical results and have published several academic papers in famous academic journals such as Nature 、Cell、Nature Medicine、Nature biotechnology. BRL Medicine has built five technology platforms with independent intellectual property rights, including The Gene Editing Technology Innovation Platform, Hematopoietic Stem Cell Platform, The Quikin CAR-T Platform, Universal Cell Platform and Enhanced T Cell Platforms, and has a 7000 square meter GMP pilot plant and an operating team of nearly 100 people, which strongly guarantees the rapid transformation and application of innovative research. BRL Medicine continuously promotes rapid update and iteration of R&D products through patient needs and clinical feedback. Driven by the era of new commercial civilization, BRL Medicine holds an open, shared, and win-win attitude, and works with global innovative biomedical ecological chain companies to accelerate the transformation and implementation of innovative drugs, so as to benefit global patients with genetic diseases and malignant tumors!
Dedicated to the development and translation of gene editing and cell therapy and gene therapy for genetic diseases caused by gene mutations
Nearly 100 people
Contains 10% PhD and 23.5% Master
125+
Has applied for 125 invention patents at home and abroad
Has five core technology platforms with independent intellectual property rights
Relying on its strong technical strength and scientific research team in the field of gene editing and immunology, BRL Medicine is dedicated to the development and translation of gene editing and cell therapy, as well as gene therapy for genetic diseases caused by gene mutations.
Awarded "CGT Awards - Most Influential Innovative Therapy Enterprise of the Year"
An RNA editor named "PA-rABE" has been developed, published in Nature Biotechnology
Awarded as "Top Ten Scientific Advancements in China" for 2024
Awarded as "Top Ten Advancements in Chinese Pharmaceutical Biotechnology in 2024"
Molecular Therapy published an article stating that an innovative CAR-T cell has been developed, significantly enhancing the efficacy of solid tumor treatment.
The study on BRL-303 treatment for autoimmune diseases was selected by Cell magazine for the "Cell Line: 2014–2024" collection.
The study on BRL-303 in the treatment of autoimmune diseases was recognized as one of the "Top Ten Advancements in Chinese Life Sciences in 2024".
The BRL-303 research was selected as one of the "Top Ten Scientific and Technological Progress Stories of 2024" by academicians from both the Chinese Academy of Sciences and the Chinese Academy of Engineering.
Awarded as "Shanghai Patent Work Exemplary Excellent Unit"
BRL-303 treatment for autoimmune diseases research was awarded "Best of Cell 2024" by Cell magazine
The research on BRL-303 for the treatment of autoimmune diseases has been selected as one of the "Top Ten Clinical Breakthroughs in the Medical Field in 2024."
The research achievements of BRL-303 were simultaneously selected as "Top 10 International Science and Technology News Stories of 2024" and "Top 10 Domestic Science and Technology News Stories of 2024"
Won the "Annual Investment Value Award" at the 5th China Biomedical Industry Chain Innovation Awards.
BRL Medicine gene therapy for China's first foreign SCD patient succeeded
Announced the completion of nearly RMB 200 million in Series B+ financing.
Won the "Excellence Award" at the Fourth Season Biomedical Tomorrow Star Industry Competition
The non-viral site-specific integration PD1-CAR-T therapy "BRL-203" has been granted an IND approval in China.
Awarded as "2024 Top 100 Chinese Pharmaceutical Innovation Seed Enterprises"
Honored with the "Top 20 Rising Companies in Biomanufacturing 2024" Award
The headline article in Nature journal reports the research findings of BRL-303 product in treating autoimmune diseases.
The first patient treated with BRL-201 has achieved cancer-free survival for over 4 years.
The research findings of BRL-303 product in treating autoimmune diseases have garnered a highly positive review from Professor Carl June, the "Father of CAR-T", which was published in Cell.
Awarded the "Top 10 Most Influential Cell Gene Therapy Enterprises" in the Huayi List·2024 China Biomedical Science and Technology Innovation Value List.
Won the "Outstanding Project" award in the Innovation Competition of the 2024 Precision Medicine Research and Industry Development Conference.
Won the "Rare Disease Industry Promotion Award," the first award in China's rare disease field, at the 4th Golden Snail Awards.
Awarded as
Awarded as
BRL Medicine's gene therapy has successfully cured 6 cases of severe β thalassaemia
Awarded as
BRL Medicine was employed as the scientific research cooperative unit of rare diseases Professional Committee of Hunan Genetic Society
Awarded
Awarded
Collaboration with East China Normal University to set up
Cooperation with the 923 Hospital of the PLA Joint Logistic Support Force has successfully cured 3 cases of severe β thalassaemia for the first time in Guangxi
Collaboration with The First Affiliated Hospital, ZHEJIANG University, the first ALL patient of the new generation UCART was cured and discharged
BRL Medicine outstanding research results were selected into the second edition of
Awarded
Launch of "Global Partner" introduction program
6000 square meters GMP pilot plant put into operation
First successful treatment of ALL patients using CD19-UCART in collaboration with The First Affiliated Hospital of Zhengzhou University
Obtained "Intellectual Property Management System Certification"
Collaborated with The First Affiliated Hospital, ZHEJIANG University to release clinical data on the world's first CD19-PD1-Quikin-CART for the successful treatment of lymphoma
Collaboration with Xiangya Hospital Central South University to release the world's first clinical data of CRISPR gene editing for the successful treatment of β0/β0 severe β thalassemia
Self-developed a new dual base editor system,published by Nature Biotechnology
Independently developed ultra-high activity HyCBE single-base editor,published by Nature Cell Biology
Next-generation single-base editing technology confirmed as promising cure for inherited blood disorders,published by Nature medicine
Awarded "2019 top 100 future medical · China list - UCAR-T TOP5"
Awarded tens of millions of dollars in funding support from the Shanghai Zhangjiang National Innovation Demonstration Zone Special Development Fund (H25)
Gene editing for thalassemia, CD19-PD1-Quikin-CART, and enhanced PSMA-CART successively initiated IIT
Awarded "2019 China's Top 50 Most Innovative Biomedical Companies"
Selected as a patent pilot enterprise in Shanghai in 2019
Gene Therapy Promises Complete Cure for Inherited Blood Disorders, published by Nature Medicine
CD19-UCART start IIT clinical trial
1000 square meters of GMP like pilot plant put into operation
Identified as “Shanghai High-Tech Enterprise”
Reorganization of Bioraylab and establishment of "Shanghai Research Center for Gene Editing and Cell Therapy"
BRL Medicine Inc. was incorporated
World's first successful application of CRISPR/Cas9 for mammalian gene editing, published by Nature Biotechnology, published by Nature Biotechnology